Life Sciences First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis AIT News Desk May 28, 2022 Anifrolumab is a first-in-class type I interferon receptor antibody The first patients have been dosed in the IRIS Phase III clinical trial of…